However, it is a challenge to measure these related AD biomarkers in serum instead of CSF, such as Tau [10], mainly because the levels of these proteins are significantly much lower in serum than in CSF, and also it is a very complex matrix from which unspecific absorption must be avoided. The gene discussed is MAPT; the disease is Alzheimer disease.